Disease · MONDO_0018555

hypogonadotropic hypogonadism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. hypogonadotropic hypogonadism. Diseases, record MONDO_0018555. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018555

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: hypogonadotropic hypogonadism; Open Targets
Open Targets ID: MONDO_0018555; Open Targets
Other names: Hypogonadotrophic hypogonadism, Isolated congenital gonadotropin deficiency, Normosmic idiopathic hypogonadotropic hypogonadism, central hypogonadism, gonadotropic deficiency, hypogonadism, hypogonadotropic, hypogonadotropic hypogonadism with or without anosmia, low gonadotropins (secondary hypogonadism), nIHH, normosmic congenital hypogonadotropic hypogonadism, secondary hypogonadism; Open Targets
Disease Ontology: DOID:0090070; Disease Ontology
Disease Ontology: DOID:7455; Disease Ontology
NCI Thesaurus: C113347; NCI Thesaurus
Orphanet: ORPHA:432; Orphanet
Highest stage of its drugs: Approval, for 3 of its 23 drugs, from DailyMed; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TESTOSTERONE	CHEMBL386630	Small molecule	Approval	DailyMed	32	7	7	Drugs and targets
FOLLITROPIN	CHEMBL4297955		Approval	DailyMed	5	3	3	Drugs and targets
TESTOSTERONE ENANTHATE	CHEMBL1200335	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ENCLOMIPHENE CITRATE	CHEMBL1200667	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
GONADOTROPIN, CHORIONIC	CHEMBL1201509	Protein	Phase 3	ClinicalTrials.gov	5	5	3	Drugs and targets
LUTROPIN ALFA	CHEMBL1201419	Protein	Phase 3	ClinicalTrials.gov	5	5	4	Drugs and targets
CHORIOGONADOTROPIN ALFA	CHEMBL1201464	Protein	Phase 3	ClinicalTrials.gov	3	3	0	Drugs and targets
CORIFOLLITROPIN ALFA	CHEMBL2108185	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
LETROZOLE	CHEMBL1444	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
MENOTROPINS	CHEMBL2108427	Protein	Phase 3	ClinicalTrials.gov	2	2	0	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets11

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	4	Estrogen receptor alpha modulator; Estrogen receptor modulator	Phase 2	https://conductscience.org/library/genes/2099	Drugs and targets
FSHR	Follicle-stimulating hormone receptor	4	Follicle stimulating hormone receptor agonist	Approval	https://conductscience.org/library/genes/2492	Drugs and targets
LHCGR	Lutropin-choriogonadotropic hormone receptor	4	Luteinizing hormone/Choriogonadotropin receptor agonist	Phase 3	https://conductscience.org/library/genes/3973	Drugs and targets
AR	Androgen receptor	3	Androgen Receptor agonist	Approval	https://conductscience.org/library/genes/367	Drugs and targets
GNRHR	Gonadotropin-releasing hormone receptor	3	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Phase 2	https://conductscience.org/library/genes/2798	Drugs and targets
CYP19A1	Aromatase	1	Cytochrome P450 19A1 inhibitor	Phase 3	https://conductscience.org/library/genes/1588	Drugs and targets
ESR2	Estrogen receptor	1	Estrogen receptor modulator	Phase 2	https://conductscience.org/library/genes/2100	Drugs and targets
INSR	Insulin receptor	1	Insulin receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3643	Drugs and targets
OPRD1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Phase 1	https://conductscience.org/library/genes/4985	Drugs and targets
OPRK1	Opioid receptors; mu/kappa/delta	1	Opioid receptors; mu/kappa/delta antagonist	Phase 1	https://conductscience.org/library/genes/4986	Drugs and targets

1 to 10 of 11

See all 11 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01534208	Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism	Phase 3	499	2014-07-24	Secondary Hypogonadism	ENCLOMIPHENE CITRATE	Its record names the disease	ClinicalTrials.gov
NCT01739595	Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism	Phase 3	181	2015-05-27	Secondary Hypogonadism	ENCLOMIPHENE CITRATE	Its record names the disease	ClinicalTrials.gov
NCT01532414	Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism	Phase 3	151	2015-05-27	Secondary Hypogonadism	ENCLOMIPHENE CITRATE	Its record names the disease	ClinicalTrials.gov
NCT01191320	Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus	Phase 2	102	2014-07-24	Type 2 Diabetes Mellitus, Secondary Hypogonadism	ENCLOMIPHENE CITRATE	Its record names the disease	ClinicalTrials.gov
NCT01270841	Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism	Phase 2	83	2014-07-28	Secondary Hypogonadism	ENCLOMIPHENE CITRATE, TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT01457703	Reproductive Hormonal Alterations in Obesity	Not applicable	62	2015-03-25	Obesity	CETRORELIX, GONADORELIN, LETROZOLE, LUTROPIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT00467987	Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism	Not applicable	47	2024-02-06	Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT01084265	A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism	Phase 3	31	2012-05-22	Hypogonadism	FOLLITROPIN, FOLLITROPIN ALFA, LUTROPIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT00064987	Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism	Phase 2	19	2017-07-07	Hypogonadism, Kallmann Syndrome	FOLLITROPIN, GONADORELIN, GONADORELIN ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01709331	A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)	Phase 3	18	2016-05-09	Hypogonadism, Hypogonadotropic Hypogonadism	CORIFOLLITROPIN ALFA, GONADOTROPIN, CHORIONIC	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Androxal 12.5 mg vs Androxal 25 mg: serious adverse events	6 of 207	9 of 283	490	NCT01534208	Trial comparisons
BMI ≥30 kg/m2 vs BMI 18-25 kg/m2: serious adverse events	0 of 29	0 of 33	62	NCT01457703	Trial comparisons
Group 1 (FSH) vs Group 2 (GnRH): deaths from any cause	0 of 10	0 of 6	16	NCT00064987	Trial comparisons
Group 1 (FSH) vs Group 2 (GnRH): serious adverse events	0 of 10	0 of 6	16	NCT00064987	Trial comparisons
Diabetes vs Control: deaths from any cause	0 of 8	0 of 6	14	NCT02154477	Trial comparisons
Diabetes vs Control: serious adverse events	0 of 8	0 of 6	14	NCT02154477	Trial comparisons
Group 1 (FSH) vs Group 2 (GnRH): Fertility	4 of 4	1 of 2	6	NCT00064987	Trial comparisons

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36107111	RESULT	1	PubMed
30515210	RESULT	1	PubMed
28270212	RESULT	1	PubMed
25131486	RESULT	1	PubMed
20382682	RESULT	1	PubMed
19829004	RESULT	1	PubMed
31132118	DERIVED	1	PubMed
30295816	DERIVED	1	PubMed
29669934	DERIVED	1	PubMed
28368486	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0018555

GET https://conductscience.org/api/diseases/v1/MONDO_0018555/drugs?page=2

API reference For AI assistants